CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer
Article first published online: 4 JUN 2012
Copyright © 2012 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 106, Issue 8, pages 999–1004, 15 December 2012
How to Cite
Lee, H. H., Seo, K. J., An, C. H., Kim, J. S. and Jeon, H. M. (2012), CD133 expression is correlated with chemoresistance and early recurrence of gastric cancer. J. Surg. Oncol., 106: 999–1004. doi: 10.1002/jso.23178
- Issue published online: 14 NOV 2012
- Article first published online: 4 JUN 2012
- Manuscript Accepted: 14 MAY 2012
- Manuscript Received: 30 OCT 2011
- CD133 antigen;
- neoplastic stem cells;
- stomach neoplasms
CD133 has been suggested to be a cancer stem cell (CSC) marker in various types of cancers. The present study assessed the relationship between CD133 expression and clinicopathological features of gastric cancer. In addition, the prognostic value of CD133 for gastric cancer was evaluated.
In total, 100 advanced gastric cancer patients who received curative gastrectomy and adjuvant chemotherapy were included. CD133 expression was determined by immunohistochemistry and clinicopathological results, including survival, were analyzed.
CD133 was expressed in 23% of advanced gastric cancer patients (23/100). CD133 expression was significantly associated with serosal exposure (P = 0.036), venous invasion (P = 0.047), well and moderate differentiation (P = 0.002), and intestinal-type Lauren classification (P = 0.001). CD133-positive patients had a significantly worse 5-year disease-free (28.1% vs. 65.8%, P = 0.002) and overall (47.5% vs. 74.0%, P = 0.037) survival rate than those who were CD133-negative. A multivariate analysis suggested that CD133 expression significantly affected the 5-year disease-free and overall survival.
CD133 may play an important role in chemoresistance and recurrence, thus representing a promising predictive marker for the prognosis of gastric cancer. J. Surg. Oncol. 2012; 106: 999–1004. © 2012 Wiley Periodicals, Inc.